'Photocisplatin' reagents

Current Opinion in Drug Discovery and Development

Volumn 8, Issue 4, 2005, Pages 478-486

  Loganathan, Devanesan ^a   Morrison, Harry ^b  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Photochemotherapy; Photocisplatin reagents; Photocytotoxicity; Photodynamic therapy; Phototoxicity

Indexed keywords

1 [2 (ACRIDIN 9 YLAMINO)ETHYL] 1,3 DIMETHYLTHIOUREA; 1,10 PHENANTHROLINE; CISPLATIN DERIVATIVE; DICHLORO (1,10 PHENANTHROLINE)(9,10 PHENANTHRENEQUINONEDIAMINE)RHODIUM CHLORIDE; DICHLORO (DIPYRIDO[3,2 A:2',3' C]PHENAZINE)(1,10 PHENANTHROLINE)RHODIUM CHLORIDE; DICHLOROBIS(1,10 PHENANTHROLINE)RHODIUM CHLORIDE; DIMETHYLTHIOUREA; DNA; METAL COMPLEX; METHOXSALEN; PHOTOCISPLATIN; RHODIUM DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PHOTOCHEMOTHERAPY; PHOTODYNAMIC THERAPY; PUVA; RAT; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; HUMANS; ORGANOPLATINUM COMPOUNDS; PHOTOCHEMISTRY; PHOTOCHEMOTHERAPY; RHODIUM; RUTHENIUM;

EID: 21444453448     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Sigel A, Sigel H (Eds): Metal Ions in Biological Systems: Metal Complexes in Tumor Diagnosis and Anticancer Agents. Marcel Dekker, Basel, Switzerland (2004).
2. Barnes KR, Lippard SJ: Cisplatin and related anticancer drugs: Recent advances and insights. Metal Ions Biol Systems (2004) 42:143-177.
3. Cohen SM, Lippard SJ: Cisplatin: From DNA damage to cancer chemotherapy. Prog Nucleic Acids Res Mol Biol (2001) 67:93-130. The most comprehensive review so far discussing cisplatin chemotherapy and its mechanism of action.
4. Fuertes MA, Castilla J, Alonso C, Pérez JM: Cisplatin biochemical mechanism of action: From cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem (2003) 10(3):257-266.
5. Fuertes MA, Castilla J, Alonso C, Pérez JM: Novel concepts in the development of platinum antitumor drugs. Curr Med Chem - Anticancer Agents (2002) 2(4):539-551.
6. Desoize B: Metals and metal compounds in cancer treatment. Anticancer Res (2004) 24(3a):1529-1544.
7. Zovinka EP, Sunseri DR: Photochemotherapy: Light dependent therapies in medicine. J Chem Ed(2002) 79(11):1331-1335. A basic introductory review of the current clinically approved light-based photochemotherapies.
8. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q: Photodynamic therapy. J Natl Cancer Inst (1998) 90(12):889-905. An excellent review of photodynamic therapy written by the pioneers of the field.
9. Dougherty TJ: An update on photodynamic therapy applications. J Clin Laser Med Surg (2002) 20(1):3-7.
10. Detty MR, Gibson SL, Wagner SJ: Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem (2004) 47(16):3897-3915.
11. Brown SB, Brown EA, Walker I: The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol (2004) 5(8):497-508.
12. Heshmati F, Andreu G: Extracorporeal photochemotherapy: A historical perspective. Transfus Apheresis Sci (2003) 28(1):25-34.
13. Knobler R, Jantschitsch C: Extracorporeal photochemoimmunotherapy in cutaneous T-cell lymphoma. Transfus Apheresis Sci (2003) 28(1):81-89. A comprehensive review of extracorporeal photopheresis, focusing especially on extracorporeal photopheresis in clinical practice.
14. Hockel M, Vaupel P: Tumor hypoxia: Definitions and current clinical, biologic and molecular aspects. J Natt Cancer Inst (2001) 93(4):266-276.
15. 6 hexacoordinate metal complexes. Coord Chem Rev (1982) 44:61-82.
16. Mahnken RE, Billadeau MA, Nikonowicz EP, Morrison H: Toward the development of photo cis-platinum reagents. Reaction of cis-dichlorobis(1,10- phenanthroline)rhodium(III) with calf thymus DNA, nucleotides and nucleosides. J Am Chem Soc (1992) 114(24):9253-9265. This initial publication describes the photobiology of BISPHEN and the concept of photocisplatin reagents as a possible therapeutic modality.
17. Billadeau MA, Morrison H: Photolytic covalent binding of metal complexes to DNA. Metal Ions Biol Sys (1996) 33:269-296. An extensive review discussing BISPHEN as a photocisplatin reagent.
18. 6 metal complexes. Prog Inorg Chem (1983) 30:213-269.
19. Metcalfe C, Thomas JA: Kinetically inert transition metal complexes that reversibly bind to DNA. Chem Soc Rev (2003) 32(4):215-224.
20. + to DNA. Photochem Photobiol (1989) 49(4):519-522.
21. Morrison H, Harmon H: "Hot spots" associated with the photoinduced binding of cis-dichloro bis(1,10-phenanthroline)rhodium(III) chloride to HIV-1 and c-Raf DNA. Photochem Photobiol (2000) 72(6):731-738.
22. Sherman SE, Lippard SJ: Structural aspects of platinum anticancer drug interactions with DNA. Chem Rev (1987) 86:1153-1181.
23. Harmon HL, Morrison H: Anaerobic photoinduced N7 binding of cis-dichlorobis(1,10-phenanthroline)rhodium(III) chloride to 2′-deoxyguanosine: A one electron transfer chain process. Inorg Chem (1995) 34(20):4937-4938.
24. +: A new family of light activatable nucleic acid cross-linking agents. Bioorg Med Chem Lett (1999) 9(12):1703-1708.
25. Caffieri S: Furocoumarin photolysis: Chemical and biological aspects. Photochem Photobiol Sci (2002) 1(3):149-157. A comprehensive general review discussing furocoumarin photochemistry, with particular emphasis on the mechanism of action.
26. Mohammad T, Tessman I, Morrison H, Kennedy MA, Simmonds SW: Photosensitized inactivation of infectious DNA by urocanic acid, indoleacrylic acid and rhodium complexes. Photochem Photobiol (1994) 59(2):189-196.
27. Terrian DL: The photochemistry and photobiology of rhodium(III) polypyridyl complexes and psoralen prodrugs. PhD Dissertation, Purdue University, West Lafayette, IN, USA (1996).
28. Dickeson JE, Summers LA: Derivatives of 1,10-phenanthroline-5,6-quinone. Aust J Chem (1970) 23(5):1023-1027.
29. Menon EL, Perera R, Navarro M, Kuhn RJ, Morrison H: Phototoxicity against tumor cells and sindbis virus by an octahedral rhodium bisbipyridyl complex and evidence for the genome as a target in viral photoinactivation. Inorg Chem (2004) 43(17):5373-5381. Describes the properties of DPPZPHEN, focusing mainly on phototoxicological properties and the mechanisms responsible for phototoxicity.
30. Menon EL: Photochemistry and phototoxicity of naturally occurring and synthetic chemicals. PhD Dissertation, Purdue University, West Lafayette, IN, USA (2003).
31. Loganathan D: Photochemical, photophysical and photobiological properties of some novel bisbipyridyl rhodium (III) complexes. PhD Dissertation, Purdue University, West Lafayette, IN, USA (2003).
32. Loganathan D, Morrison H: Effect of ring methylation on the photophysical, photochemical and photobiological properties of cis-dichloro bis(1,10-phenanthroline)rhodium(III) chloride. Photochem Photobiol (2005): manuscript submitted. Describes how polymethylation of the phenanthroline ligands increases the photobiological properties of BISPHEN with respect to its possible application in photochemotherapy.
33. Loganathan D, Rodriguez JH, Morrison H: Photoaquation of methylated cis-dichlorobis(1,1O-phenanthroline)rhodium(III)-chloride compounds by direct population of a photoactive triplet excited state. J Am Chem Soc (2003) 125(19):5640-5641.
34. 5-intercalator conjugate could be used as a possible photocisplatin reagent.
35. Baruah H, Rector CL, Monnier SM, Bierbach U: Mechanism of action of non-cisplatin type DNA-targeted platinum anticancer agents: DNA interactions of novel acridinylthioureas and their platinum conjugates. Biochem Pharmacol (2002) 64(2):191-200.
36. Martins ET, Baruah H, Kramarczyk J, Saluta G, Day CS, Kucera GL, Bierbach U: Design, synthesis and biological activity of a novel non-cisplatin type platinum-acridine pharmacophore. J Med Chem (2001) 44(25):4492-4496.
37. 3, py). Inorg Chem (2001) 40(6):1376-1379.
38. Sorasaenee K, Fu PK, Angeles-Boza AM, Dunbar KR, Turro C: Inhibition of transcription in vitro by anticancer active dirhodium(II) complexes. Inorg Chem (2003) 42(4):1267-1271.
39. 2+. Inorg Chem (2001) 40(11):2476-2477.
40. 4. Inorg Chem (2004) 43(8):2450-2452.
41. Angeles-Boza AM, Bradley PM, Fu PK, Wicke SE, Basca J, Dunbar KR, Turro C: DNA binding and photocleavage in vitro by new dirhodium(II) DPPZ complexes: Correlation to cytotoxicity and photocytotoxicity. Inorg Chem (2004) 43(26):8510-8519. Discusses the possible use of polymetallic complexes, such as Rh(II)-Rh(II) complexes, as photochemotherapeutic agents.
42. Hall MD, Dolman RC, Hambley TW: Platinum(IV) anticancer complexes. Metal Ions Biol Sys (2004) 42:297-322.
43. Kratochwil NA, Bednarski PJ, Mrozek H, Vogler A, Nagle JK: Photolysis of an iodoplatinum(IV) diamine complex to cytotoxic species by visible light. Anticancer Drug Des (1996) 11(2):155-171.
44. 2(en)]: A novel type of cisplatin analog that can be photolyzed by visible light to DNA-binding and cytotoxic species in vitro. J Med Chem (1996) 39(13):2499-2507.
45. Kratochwil NA, Parkinson JA, Bednarski PJ, Sadler PJ: Nucleotide platination induced by visible light. Angew Chem Int Ed (1999) 38(10):1460-1463.
46. Kašpárková J, Mackay FS, Brabec V, Sadler PJ: Formation of platinated GG cross-links on DNA by photoactivation of a platinum (IV) azide complex. J Biol Inorg Chem (2003) 8(7):741-745. Describes the highly selective cross links on DNA photoinduced by platinum(IV) complexes.
47. Müller P, Schröder B, Parkinson JA, Kratochwil NA, Coxall RA, Parkin A, Parsons S, Sadler PJ: Nucleotide cross-linking induced by photoreactions of platinum(IV)-azide complexes. Angew Chem Int Ed (2003) 42(3):335-339. Describe platinum(IV) azide complexes as highly efficient, base-selective DNA photo cross-linking agents.
48. 2+. Inorg Chem (2004) 43(23):7260-7262.
49. PURDUE RESEARCH FOUNDATION (Morrison H, Menon EL, Loganathan D): Photoactivated anti-viral and anti-cancer agent. WO-200401266,7 (2004). Describes various analogs of BISPHEN and their properties, especially photobiological properties.